LAVA Therapeutics N.V. (LVTX) Financials

LVTX Assets vs Liabilities

DateAssetsLiabilities
March 31, 2025 71.2 million 45.4 million
Dec. 31, 2024 80.8 million 53.1 million
Sept. 30, 2024 83.4 million 50.4 million
June 30, 2024 92.3 million 49.4 million

LVTX Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2025 2.0 million 540000
Dec. 31, 2024 -1.4 million 590000
Sept. 30, 2024 -8.7 million 720000
June 30, 2024 -8.4 million 821000

LVTX Net Income

No data available :(

LVTX Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2025 66.6 million 6000 312000
Dec. 31, 2024 76.6 million 80000 395000
Sept. 30, 2024 78.9 million 164000 534000
June 30, 2024 86.8 million 295000 780000

LVTX Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2025 26.9 million
Dec. 31, 2024 26.9 million
Sept. 30, 2024 26.8 million
June 30, 2024 26.8 million

LVTX Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2025 - 4.2 million 3.4 million -
Dec. 31, 2024 - 7.6 million 4.5 million -
Sept. 30, 2024 23000 8.5 million 2.8 million -
June 30, 2024 3 6.3 million 3.0 million 228000

LVTX Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2025 - -
Dec. 31, 2024 5.0 million 228000
Sept. 30, 2024 - -
June 30, 2024 227999 228000

LVTX

Price: $1.74

52 week price:
0.85
2.00

Payout Ratio Range:
-362.12%
-23.88%

Earnings Per Share: -0.87 USD

P/E Ratio: -2

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: Netherlands

Volume: 12191

Market Capitalization: 45.8 million

Links: